Related Experiment Video
Updated: Dec 23, 2025
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
18.3K
Angiotensin receptor blockers and COVID-19.
1Department of Pharmacology and Physiology, Georgetown University Medical Center, 3900 Reservoir Road, NW, Washington D.C. 20057, USA.
Pharmacological Research
|April 19, 2020
Summary
Angiotensin Receptor Blockers (ARBs) offer lung protection against viral infections like coronavirus by reducing inflammation. Continued ARB therapy is crucial for patients with hypertension, diabetes, and kidney disease, especially during the COVID-19 pandemic.
Area of Science:
- Pharmacology
- Immunology
- Virology
Background:
- Angiotensin Receptor Blockers (ARBs) possess anti-inflammatory and direct lung-protective effects beyond blood pressure regulation.
- These effects are particularly relevant for viral respiratory infections, including coronaviruses.
- ARBs enhance the protective role of Angiotensin-Converting Enzyme 2 (ACE2).
Discussion:
- The pleiotropic effects of ARBs suggest a potential role in mitigating lung injury caused by viral pathogens.
- Continuation of ARB therapy is recommended for hypertensive, diabetic, and renal disease patients, who are at higher risk for severe COVID-19 outcomes.
- The interaction between ARBs and the ACE2 pathway warrants further investigation in the context of viral infections.
Key Insights:
- ARBs demonstrate significant protective effects on lung tissue against viral infections.
- The anti-inflammatory properties of ARBs contribute to their therapeutic potential.
- Enhanced ACE2 activity via ARB administration offers a novel protective mechanism.
Outlook:
- Further clinical studies are needed to evaluate ARBs as an adjunctive therapy for COVID-19 patients.
- Investigating ARB efficacy in different viral respiratory diseases is a promising research direction.
- Understanding the precise mechanisms of ARB-mediated lung protection could lead to new therapeutic strategies.
More Related Videos
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.2K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.1K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
811
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
811
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.2K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
01:17Antihypertensive Drugs: Action of β1 Blockers
1.8K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.8K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
356
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
356